Trevena’s (TRVN) Neutral Rating Reaffirmed at HC Wainwright

Trevena (NASDAQ:TRVN)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $5.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 195.86% from the stock’s current price.

Separately, StockNews.com started coverage on Trevena in a report on Monday. They issued a “sell” rating on the stock.

Trevena Stock Down 0.6 %

Shares of TRVN stock traded down $0.01 during mid-day trading on Thursday, hitting $1.69. 4,068 shares of the company’s stock were exchanged, compared to its average volume of 25,979. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The stock has a market cap of $1.45 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. The stock has a 50-day simple moving average of $3.15 and a two-hundred day simple moving average of $5.72.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million during the quarter. As a group, analysts anticipate that Trevena will post -32.25 earnings per share for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.